Alim Louis Benabid

Alim Louis Benabid

Alim-Louis Benabid, MD, PhD in conversation at a scientific conference in 2013
Born (1942-05-02) May 2, 1942
Occupation Neurosurgeon, researcher
Education MD, PhD
Alma mater Joseph Fourier University
Subject Medicine, Physics

Alim Louis Benabid is an French emeritus professor, neurosurgeon and member of the French Academy of Sciences, who has had a global impact in the development of deep brain stimulation (DBS) for Parkinson's disease and other movement disorders. He became emeritus professor of biophysics at the Joseph Fourier University in Grenoble in September 2007, and chairman of the board of the Edmond J. Safra Biomedical Research Center in 2009 at Clinatec, a multidisciplinary institute he co-founded in Grenoble that applies nanotechnologies to neurosciences.

Biography

Alim Louis Benabid was born May 2, 1942 in Grenoble, France. The son of a doctor from Algeria, Benabid was quoted as saying he could not easily decide between studying physics or medicine.[1] He received his medical degree in 1970 and a doctorate in physics in 1978, both from Joseph Fourier University (now part of Universite Grenoble Alpes) in Grenoble.[1] He became a staff neurosurgeon at Joseph Fourier University in 1972, professor of experimental medicine in 1978, and professor of biophysics from 1983 – 2007.[2] Benabid also had a fellowship in 1979 – 1980 in preclinical neuropharmacology in the laboratory of Floyd Bloom at the Salk Institute in La Jolla, California.[3] From 1988 – 2007, he directed the preclinical neurosciences unit at the French biomedical and public health research institution INSERM, and from 1989 – 2007, served as head of the neurosurgery department at the University Hospital of Grenoble.[2] In other roles, Benabid coordinated the Claudio Munari Center for Surgery of Epilepsy and Movement Disorders at Ospedale (Hospital) Niguarda in Milan, Italy from 1998 to 2007, and was a staff consultant at the Cleveland Clinic Foundation in Ohio from 2000 to 2003.[3]

In 2007, Benabid joined the French Commissariat d’Energie Atomique (CEA - France's nuclear and renewable energy commission) as a scientific adviser during the time a campus for public-private innovation was being created, the Grenoble Innovation for Advanced New Technologies (Giant) campus, which includes the Minatec research complex and the life-science cluster NanoBio.[4][5][6] In 2009, he became chairman of the board of the Edmond J. Safra Biomedical Research Center at Clinatec, a translational biomedical technology organization he helped found within Minatec. Clinatec was jointly created by CEA-LETI (Laboratoire d'électronique des technologies de l'information—an applied micro- and nanotechnology subsidiary of CEA), Grenoble University Hospital, INSERM and Joseph Fourier University.[7][8][9] In 2013, when awarding Benabid a $100,000 Robert A. Pritzker Prize for Leadership in Parkinson's Research to fund continued research, the Michael J. Fox Foundation said in its award announcement that Benabid had published 523 scientific papers, achieving an H Index of 67, as well as given 18 honorary lectures, and received 23 medals and prizes.[3]

Deep brain stimulation neurosurgery

Benabid developed stereotactic surgery methods for brain surgery in patients who had brain tumors or certain types of movement disorder.[2]

As part of the work, he and his team members created tissue banks using tissue from brain tumor biopsies. The tissue samples were used to characterize brain tumors by oncogenic mapping. Studies of genomics and proteomics have highlighted the factors involved in tumor progression and led to therapeutic advances such as anti-angiogenic factors.[2]

For patients suffering from Parkinson's disease, Benabid and Pierre Pollak, a neurologist at the University Hospital of Grenoble, also developed deep brain stimulation (DBS) in 1987.[1][10][11]

Parkinson's disease is commonly treated with medicines such as levodopa to improve muscle control, balance and walking, but higher dosages tend to be needed over time in this progressive neurological condition, and long-term use can lead to motor fluctuations such as tremor, rigidity or slowness.[12]

Prior to development of DBS, the main surgical treatment for Parkinson's disease was lesioning to inhibit involuntary abnormal motion associated with severe Parkinson's disease not controlled by optimal medication.[9] As described in a 2010 interview with Benabid in the medical journal Lancet,[13] electrical stimulation was used during surgery to locate the ablation target and predict lesioning effects. To precisely locate the right area, an electrode would be placed around the target and those surrounding areas stimulated with physiological frequencies of 20 – 50 Hz while observing the patient's movement. Since electrical stimulation itself sometimes seemed to quiet tremor during the procedure, Benabid reasoned this might be a solution. He tested from very low frequencies of 1, 5, 10 Hz and more up to 100 Hz, which mimicked effects of ablation without destroying tissue. Initially the thalamus was stimulated. Later animal studies indicated the subthalamic nucleus might be a more effective stimulation target. As technology advanced to allow such stimulation to be continuously applied for a long time, DBS became widely adopted in the 1990s for treatment of movement disorders such as Parkinson's disease, essential tremor, and dystonia.[1][14]

A meta-analysis of six randomized controlled trials published in 2014 showed that in 1,184 study subjects, DBS significantly improved untreated motor symptoms of Parkinson's disease, permitting a reduction in medication doses and their associated complications; as well as contributing moderately, during the phase when the patients were taking Parkinson's disease medication, to fewer motor symptoms, greater function, and more quality of life.[15]

Honors and awards

As detailed in his 2008 biography by the French Academy of Sciences[2] and more recent news releases,[3][16][17] Dr. Benabid has received a number of awards and honors, including:

See also

References

  1. 1 2 3 4 Williams, Ruth (December 2010). "Alim-Louis Benabid: stimulation and serendipity". The Lancet. Elsevier Ltd. 9 (12): 1152. doi:10.1016/S1474-4422(10)70291-X. Retrieved Feb 9, 2014.
  2. 1 2 3 4 5 "Notice biographique de Alim-Louis Benabid, Membre de l'Académie des sciences" (PDF) (in French). December 2, 2008. Retrieved March 1, 2014.
  3. 1 2 3 4 "PARKINSON'S RESEARCHER PROFILE Alim Louis Benabid, MD, PhD". The Michael J. Fox Foundation for Parkinson's Research. Retrieved March 1, 2014.
  4. ↑ Prest, Michael (19 January 2010). "A technological powerhouse to rival MIT and Oxbridge: The French are waking the sleeping giant". The Independent. Retrieved March 1, 2014.
  5. ↑ Reisz, Matthew (11 March 2010). "Grenoble takes Giant steps towards collaboration". Times Higher Education. Retrieved March 1, 2014.
  6. ↑ fr:NanoBio
  7. ↑ Mestais, Corrine (May 2009). "CLINATEC® leverages micro and nanotechnologies for healthcare". MINA-NEWS. Life@MINATEC. Retrieved March 1, 2014.
  8. ↑ Berger, Francois. "CLINATEC: A Technology Translational Research Center". Diplomacy & Foreign Affairs. Retrieved March 1, 2014.
  9. 1 2 "Smart Machines – Neural Evolution IFESS Conference 2012: Speaker Alim Louis Benabid". International Functional Electrical Stimulation Society (IFESS). January 19, 2012. Retrieved March 1, 2014.
  10. ↑ Benabid, A.L. (December 2003). "Deep brain stimulation for Parkinson's disease". Current Opinion in Neurobiology. 13 (6): 696–706. doi:10.1016/j.conb.2003.11.001.
  11. ↑ Herpich, Nate (May 28, 2013). "Robert A. Pritzker Prize Winner's 'Serendipitous Discovery' Leads to Improved Lives for Many with Parkinson's". The Michael J. Fox Foundation for Parkinson's Research. Retrieved March 1, 2014.
  12. ↑ Lee, Chong S. (May 2001). "Levodopa-induced dyskinesia: Mechanisms and management". BCMJ. 43 (4): 206–209.
  13. ↑ thelancet.com
  14. ↑ Berger, Pierre-Damien (July 5, 2013). "CLINATEC Chairman Alim-Louis Benabid Honored by Michael J. Fox Foundation for Pioneering Work in Treating Parkinson's Disease". BusinessWire. Retrieved March 1, 2014.
  15. ↑ Perestelo-Pérez, L.; A. Rivero-Santana; J. Pérez-Ramos; P. Serrano-Pérez; J. Panetta; P. Hilarion (Feb 2, 2014). "Deep brain stimulation in Parkinson's disease: meta-analysis of randomized controlled trials". Journal of Neurology. Springer Berlin Heidelberg. 261 (11): 2051–60. doi:10.1007/s00415-014-7254-6. PMID 24487826. Retrieved March 1, 2014.
  16. ↑ Berger, Pierre-Damien (Oct 9, 2013). "CLINATEC Chairman Alim-Louis Benabid Honored By U.S. Research Institute for Parkinson's Disease Work". BusinessWire. Retrieved March 1, 2014.
  17. ↑ "Clinatec Chairman Alim-Louis Benabid Wins $3 Million 2015 Breakthrough Prize in Life Sciences for Parkinson's Disease Work". BusinessWire. Nov 10, 2014. Retrieved Nov. l1, 2014. Check date values in: |access-date= (help)

External links

This article is issued from Wikipedia - version of the 10/26/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.